Longeveron Inc
LGVN
NASDAQ
Biotechnology
$0.74
USD
+0.04 (+6.06%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $22.04M
Volume 297.6K
Revenue
$1.19M
TTM
-42.7%
YoY
Gross Margin
70%
TTM
-11.4%
YoY
Net Income
$-23.47M
TTM
-26.6%
YoY
Operating Cash Flow
$-20.37M
TTM
-40.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.3 | 0.1 | 0.4 | 0.4 | 0.3 |
YoY Growth | -32.5% | -82.3% | -39.5% | +4.5% | -9.2% |
Cost of Revenue | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 |
Gross Profit | 0.1 | 0.1 | 0.3 | 0.3 | 0.2 |
Selling, General & Administrative | 2.6 | 3.6 | 2.9 | 2.7 | 3.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 5.5 | 7.4 | 5.7 | 5.0 | 6.4 |
Operating Income | -5.4 | -7.3 | -5.4 | -4.8 | -6.2 |
EBITDA | -5.1 | -7.0 | -5.1 | -4.5 | -6.0 |
Other Income / Expense | 0.4 | 0.1 | -0.0 | 0.0 | 0.1 |
Total Other Income / Expense | 0.4 | 0.1 | -0.0 | 0.0 | 0.1 |
Income Before Income Taxes | -5.0 | -7.2 | -5.4 | -4.7 | -6.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -5.0 | -7.2 | -5.4 | -4.7 | -6.1 |
Consolidated Net Income / Loss | -5.0 | -7.2 | -5.4 | -4.7 | -6.1 |
Net Income Attributable to Common Shareholders | -5.0 | -7.2 | -5.4 | -4.7 | -6.1 |
Basic EPS | -$0.33 | -$0.39 | -$0.25 | -$0.19 | -$0.19 |
Diluted EPS | -$0.33 | -$0.39 | -$0.25 | -$0.19 | -$0.19 |
Basic Shares Outstanding | 15.0M | 18.4M | 22.0M | 24.8M | 31.4M |
Diluted Shares Outstanding | 15.0M | 18.4M | 22.0M | 24.8M | 31.4M |